Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.51
UNSPSC Code:
41105324
description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
GCTGGAGGTCCTATCAGCAGTATCTTGGTGAATAAATACGGCAGCCGTCCAGTAATGATCGCTGGTGGTTGTCTGTCTGGTTGCGGCTTGATCGCAGCTTCTTTCTGTAACACAGTACAGGAACTTTACTTGTGCATTGGTGTTATTGGAGGTCTTGGGCTTGCTTTCAACTTGAACCCAGCTCTGACTATGATTGGCAAGTATTTCTACAAGAAGCGACCACTGGCCAACGGACTGGCCATGGCAGGCAGCCCTGTGTTCCTCTCTACCCTGGCTCCACTTAATCAGGCTTTCTTTGATATTTTTGACTGGAGAGGAAGCTTCCTAATTCTTGGGGGCCTCCTCCTAAATTGTTGTGTAGCTGGATCCCTGATGAGACCAATAGGGCCTGAGCAAGTCA
Ensembl | mouse accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
mouse ... SLC16A1(20501), Slc16a1(20501)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
C J De Saedeleer et al.
Oncogene, 33(31), 4060-4068 (2013-10-30)
The glycolytic end-product lactate is a pleiotropic tumor growth-promoting factor. Its activities primarily depend on its uptake, a process facilitated by the lactate-proton symporter monocarboxylate transporter 1 (MCT1). Therefore, targeting the transporter or its chaperon protein CD147/basigin, itself involved in
Chunxiao Yan et al.
International journal of clinical and experimental pathology, 8(3), 2710-2718 (2015-06-06)
This study was designed to investigate the role of MCT1 in the development of cisplatin-resistant ovarian cancer and its possible relationship with Fas. We found the expression of MCT1 was obviously increased both in cisplatin-resistant ovarian cancer tissue and A2780/CP